Rasagiline Besylate is a monoamine oxidase-B (MAO-B) selective inhibitor used clinically to treat the motor symptoms of Parkinson's disease. As a derivative of propargylamine, this pharmaceutical agent… Read more
Rasagiline Besylate is a monoamine oxidase-B (MAO-B) selective inhibitor used clinically to treat the motor symptoms of Parkinson's disease. As a derivative of propargylamine, this pharmaceutical agent works by inhibiting the breakdown of dopamine in the brain. Analytical laboratories require high-quality reference standards of the active pharmaceutical ingredient, along with its pharmacopeial and non-pharmacopeial impurities, to ensure accurate quality control and regulatory compliance. The availability of these specific related compounds allows researchers to perform comprehensive impurity profiling and rigorous method validation. Additionally, stable isotope labelled compounds are critical internal standards for precise quantification during complex bioanalytical studies. By utilizing these materials, scientists can effectively identify degradation products and maintain the integrity of analytical methods throughout the drug development and manufacturing lifecycle of this potent neurological treatment.